HLA-A and pancreatic neoplasm: To screen mutant KRAS–reactive T cells from PBMCs of human pancreatic cancer patients more precisely, we used the peptide/MHC prediction algorithms NetMHC pan4.0 and NetMHC 4.0 (32, 33) to predict potential immunogenic KRAS neoantigens and found that the HLA-A*11:01–restricted KRAS G12V 9-mer (VVGAVGVGK) was predicted to bind strongly to HLA-A*11:01 (Supplemental Tables 1 and 2).